Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Venetoclax Monotherapy in Relapsed or Refractory Waldenstrom Macroglobulinemia / Lymphoplasmacytic Lymphoma (Japan)
jRCT2031250757Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in Waldenström macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Major Response (IgM ≥ 500 mg/dL, IRC-assessed) and Number of Participants with Major Response in participants with IgM ≥ 500 mg/dL. Started Mar 2026; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on jRCT2031250757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250757.